세계의 자가세포 치료 시장 보고서(2025년)
Autologous Cell Therapy Global Market Report 2025
상품코드 : 1821715
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

자가세포 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 CAGR은 17.6%를 나타낼 것으로 예측되고 232억 2,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 재생 의학의 지속적인 성장, 의료 전문 분야 전반에 걸친 확대된 용도, 세포 배양 기술의 발전, 투자 및 연구 계획 증가, 규제 지원, 표준화 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 자동화 제조 기술 개발, 치료 전략에의 바이오마커 통합, 현장 진단(Point-of-Care) 세포 처리 기술의 등장, 조혈모세포 외의 적용 범위 확대, 산업 내 협력 및 파트너십 등이 포함됩니다.

향후 5년간 17.6% 성장이라는 예측치는 이전 전망 대비 0.2% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향에 기인합니다. 관세 장벽은 싱가포르와 이탈리아에서 원하는 세포 처리 시스템 및 냉동 보존 매체의 비용을 증가시켜 맞춤형 치료 지연과 암 치료 센터 비용 상승을 초래함으로써 미국 재생의학 발전을 저해할 것으로 예상됩니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더욱 광범위하게 나타날 것입니다.

만성 질환의 급증하는 유병률은 자가세포 치료의 확장을 촉진할 것으로 보입니다. 1년 이상 지속되는 만성 질환은 지속적인 의료적 관리가 필요하다. 자가세포 치료는 환자의 배양 및 증식된 세포를 다시 환자에게 주입하는 방식으로, 이러한 질환의 관리 및 치료에 유망한 기록을 남길 것으로 기대됩니다. 미국 국립의학도서관의 2023년 1월 보고서에 따르면, 2050년까지 미국에서 만 50세 이상 인구 중 최소 한 가지 만성 질환을 가진 사람이 1억 4,266만 명 있을 것으로 전망됩니다. 따라서 만성 질환의 증가하는 유병률은 자가세포 치료 시장 성장을 촉진합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Autologous cell therapy stands as a method within cell therapy where an individual's cells are gathered, processed, and subsequently reintroduced into their own body to address therapeutic needs. It plays a vital role in regenerative medicine, aiming to repair, replace, or rejuvenate damaged tissues or organs.

Within autologous cell therapy, two primary types are prevalent, autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy, a specific facet of this therapy, harnesses stem cells sourced from the patient's own body for therapeutic purposes. These stem cells are derived from various sources such as bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, among others. Their applications span across a wide spectrum of medical areas, including cancer, neurodegenerative disorders, cardiovascular issues, autoimmune conditions, orthopedics, and wound healing. This therapy finds application across multiple sectors including hospitals, clinics, ambulatory centers, academic and research institutions, and other healthcare settings, serving as a versatile approach in addressing various health challenges.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The autologous cell therapy market research report is one of a series of new reports from The Business Research Company that provides autologous cell therapy market statistics, including autologous cell therapy industry global market size, regional shares, competitors with a autologous cell therapy market share, detailed autologous cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. This autologous cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autologous cell therapy market size has grown rapidly in recent years. It will grow from $10.28 billion in 2024 to $12.14 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth in the historic period can be attributed to advancements in regenerative medicine, increased prevalence of chronic diseases, enhanced understanding of cellular biology, patient preference for personalized medicine, clinical success and positive outcomes.

The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $23.22 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to continued growth in regenerative medicine, expanding applications across medical specialties, advancements in cell culture techniques, increasing investment and research initiatives, regulatory support, and standardization. Major trends in the forecast period include the development of automated manufacturing technologies, integration of biomarkers in treatment strategies, the emergence of point-of-care cell processing, expansion beyond hematopoietic stem cells, collaborations, and partnerships in the industry.

The forecast of 17.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. regenerative medicine by increasing the cost of cell processing systems and cryopreservation media sourced from Singapore and Italy, thereby delaying personalized therapies and elevating cancer treatment center costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The burgeoning prevalence of chronic diseases is poised to fuel the expansion of autologous cell therapy. Chronic diseases, persisting for more than a year, necessitate continual medical attention. Autologous cell therapy, leveraging an individual's cultivated and amplified cells reintroduced into the donor, holds promise in managing and treating such conditions. According to the National Library of Medicine's January 2023 report, the US is projected to witness 142.66 million people aged 50 and above with at least one chronic condition by 2050. Hence, the heightened prevalence of chronic diseases propels the growth of the autologous cell therapy market.

The increasing aging population is expected to drive the growth of the autologous cell therapy market in the coming years. An aging population refers to the rise in median age within a population due to declining fertility rates and longer life expectancy. Autologous cell therapies can benefit this demographic by providing targeted and personalized treatment options. For instance, in July 2024, the Office of National Statistics, a UK-based producer of official statistics, reported that in 2022, approximately 12.7 million people in the UK were aged 65 and over, representing 19% of the total population. Projections indicate that by 2072, this figure could rise to 22.1 million, making up 27% of the population. Consequently, the growing aging population is fueling the expansion of the autologous cell therapy market.

Technological advancements emerge as a prominent trend shaping the autologous cell therapy market. Market leaders are automating the process to enhance efficiency and ensure sustainability. Lonza, for instance, unveiled the Cocoon Platform in April 2022, a cutting-edge technology streamlining personalized cell and gene therapy manufacturing. This platform, driven by an automated closed system, minimizes contamination risk, upholds manufacturing sterility, substantially bolsters quality, reduces labor and material expenses, and facilitates the scalable production of autologous T-cell products.

Major players in the autologous cell therapy realm are forging strategic partnerships and collaborations to fortify their market positions. Strategic partnerships, fostering collaborative endeavors between multiple entities, aim to achieve specific business objectives. Notably, in March 2022, Novartis inked an initial agreement with Carisma Therapeutics, aiming to manufacture HER 2 targeted CAR-M cell therapy. The collaboration involves transferring Carisma Therapeutics' manufacturing process to Novartis' Cell Therapy Site in the US, scheduling clinical manufacturing to commence in 2023, focusing on treating solid tumors in initial trials.

In October 2023, Clade Therapeutics, a US-based cell therapy company, successfully acquired Gadeta B.V. for an undisclosed sum. This strategic acquisition significantly enriches Clade's repertoire by incorporating innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies tailored for cancer patients into its existing portfolio. Gadeta B.V., based in the Netherlands, specializes in the development of cell therapies.

Major companies operating in the autologous cell therapy market include Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation

North America was the largest region in the autologous cell therapy market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autologous Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autologous cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for autologous cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The autologous cell therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Autologous Cell Therapy Market Characteristics

3. Autologous Cell Therapy Market Trends And Strategies

4. Autologous Cell Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autologous Cell Therapy Growth Analysis And Strategic Analysis Framework

6. Autologous Cell Therapy Market Segmentation

7. Autologous Cell Therapy Market Regional And Country Analysis

8. Asia-Pacific Autologous Cell Therapy Market

9. China Autologous Cell Therapy Market

10. India Autologous Cell Therapy Market

11. Japan Autologous Cell Therapy Market

12. Australia Autologous Cell Therapy Market

13. Indonesia Autologous Cell Therapy Market

14. South Korea Autologous Cell Therapy Market

15. Western Europe Autologous Cell Therapy Market

16. UK Autologous Cell Therapy Market

17. Germany Autologous Cell Therapy Market

18. France Autologous Cell Therapy Market

19. Italy Autologous Cell Therapy Market

20. Spain Autologous Cell Therapy Market

21. Eastern Europe Autologous Cell Therapy Market

22. Russia Autologous Cell Therapy Market

23. North America Autologous Cell Therapy Market

24. USA Autologous Cell Therapy Market

25. Canada Autologous Cell Therapy Market

26. South America Autologous Cell Therapy Market

27. Brazil Autologous Cell Therapy Market

28. Middle East Autologous Cell Therapy Market

29. Africa Autologous Cell Therapy Market

30. Autologous Cell Therapy Market Competitive Landscape And Company Profiles

31. Autologous Cell Therapy Market Other Major And Innovative Companies

32. Global Autologous Cell Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autologous Cell Therapy Market

34. Recent Developments In The Autologous Cell Therapy Market

35. Autologous Cell Therapy Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기